

**Pfizer Limited**

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 6, 2016

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001

The Manager
Listing Dept.
The National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sirs,

Sub: Press Release

Please find enclosed press release for the financial results for the quarter and financial year ended March 31, 2016.

Please take the above on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

Encl: A/a



Press Release
For immediate dissemination

Pfizer Limited revenue up by 12 % for the year ended March 31, 2016

Pfizer Limited announced its audited results for the year ended March 31, 2016.

May 6, 2016: Pfizer Limited reported a revenue growth of 12 % for the fourth quarter ended March 31, 2016 to Rs. 509.15 Cr. Revenue growth has been driven by double digit performance on a number of key brands like Becosules, Corex, Prevenar and Gelusil.

The revenue for the financial year ended March 31, 2016 increased by 9% to Rs. 1,994.86 Cr.

Profit before Tax & Exceptional items

Q4: Profit before tax and exceptional items at Rs. 119.55 Cr in Q4, 15-16 grew by 60 % as compared to Rs. 75 Cr. for the sequential period.

FY 2015-16: Profit before tax and exceptional items for the financial year ended March 31, 2016, increased by 23 % to Rs. 392 Cr.

EBITDA

EBITDA for Q4 and financial year ended March 31, 2016, is at 23.9% and 21.4% respectively.

Dividend

The Board has recommended a dividend of Rs. 15.00 per equity share of Rs. 10 each (150%) for the financial year ended March 31, 2016.

For more information,

Investors:

Prajeet Nair

Pfizer Limited

Ph.: +91-22-66932352

Email: prajeet.nair@pfizer.com

Media:

Saritha Rajeev Hajare

Pfizer Limited

+ 91 9619990917

saritha.hajare@pfizer.com

About Pfizer Limited:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advice may be obtained and necessary due diligence, investigation etc. may be done at your end.